Replimune will again submit its melanoma drug for approval

May 29, 2026 11:07 AM EDT FDA+ Replimune to ask FDA for re-re­view of melanoma drug, as agency stands by past re­jec­tions Max Bayer Senior Reporter Third time’s the charm? Replimune an­nounced Fri­day that it will sub­mit its ad­vanced melanoma drug RP1 for FDA re­view af­ter two … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER